Haemophilus influenzae is an important cause of respiratory tract infections, particularly in elderly persons. It is the major bacterial pathogen in acute exacerbations of chronic bronchitis (AECB) and also causes otitis media and sinusitis. In many cases, treatment is empiric, and there is a lack of understanding of resistance issues with this bacterium. There is little understanding of the epidemiology of H. influenzae respiratory infections, although some strains may be replaced by new strains that cause more severe infections. There is almost no information on how these bacteria may spread in the community. Ampicillin resistance is significant (it may be 130%), and there are few oral agents capable of reducing organism burden. There is little understanding of the epidemiology of H. influenzae respiratory infections, and almost no information on how these bacteria may spread in the community. Recent evidence suggests that these bacteria may behave in a similar way to Streptococcus pneumoniae. If that proves correct, then it will be important to follow these organisms in the community to determine if resistance determinants may spread more widely than we have thus far believed. The implications for treatment, infection prevention and control, and public health should not be underestimated as it has been with other organisms such as S. pneumoniae and Staphylococcus aureus.
in prevalence worldwide and clinical consideration and treatment for each of these infectious diseases varies between countries. However, consistency in accurate diagnosis and treatment for H. influenzae respiratory infections remains important.
H. influenzae is classified into 3 main categories: nonencapsulated strains, encapsulated type b strains, and encapsulated non-type b strains (types a and c-f). Encapsulated type b strains are those predominantly involved in nasopharyngeal colonization and subsequent pneumonia/meningitis infections in children [1] . However, since the introduction of the conjugate H. influenzae type b (Hib) vaccine, colonization rates have decreased dramatically, as has the incidence of H. influenzae type b meningitis [1, 2] . In fact, it has been voiced on more than one occasion that, in many countries, newer physicians may never see a case of H. influenzae type b meningitis. The concern is that other encapsulated, non-type b strains that have significant virulence or that may have been exposed to antimicrobials in other body systems (e.g., respiratory tract) may gradually replace type b strains in serious invasive infections. This added specter of drug resistance would be cause for alarm. There are already recently identified cases of type a invasive disease in Alaska and in native populations in the North West Territories of North America. Fortunately these strains have remained broadly susceptible thus far (W. Vaudry and G. Tyrrell, personal communications).
Unfortunately, for infections caused by nontypable H. influenzae, such as AECOPD, AECB, pneumonia, sinusitis, or otitis media, vaccines are not available, and many persons remain at risk. As a cause of CAP, H. influenzae ranks second to S. pneumoniae and causes 13%-15% of all known cases [3] . In AECB, H. influenzae is the main pathogen at 130% of cases [4] . We also know that AECB increases markedly in elderly persons, and in persons with pre-existing lung conditions. Another factor for consideration is the role smoking plays as a major risk factor for AECB. The importance of H. influenzae infection in these persons cannot be underestimated. Further, recent evidence suggests that acquisition of new strains of H. influenzae, and other respiratory pathogens, may significantly increase the risk of AECB [5] .
Maintaining an armamentarium of potent agents that eradicate H. influenzae successfully and quickly is essential. Treatment with agents, such as newer fluoroquinolones, that reach high concentrations in the lung and to which the organism is exquisitely susceptible can reduce morbidity significantly. In infections for which H. influenzae is either suspected or proven, primary b-lactam therapy with ampicillin or amoxicillin is problematic. As shown in table 1, depending on the source of strains, anywhere from 6%-43% are ampicillin resistant (TARGETed surveillance data) [7] . The resistance in these strains is usually mediated by a TEM-1 b-lactamase enzyme, which is susceptible to the binding of clavulanic acid; thus, the addition of clavulanic acid to amoxicillin brings susceptibility rates back to 100%.
Most treatment protocols for CAP or AECB include a newer macrolide as a primary choice [6] . Table 1 shows that, globally, almost all strains of H. influenzae are thus far susceptible to azithromycin as a marker macrolide agent. However, a number of these strains have MICs that are clearly resistant (8 mg/L) and, MIC 50 values are 1 mg/L. As our understanding of the pharmacokinetics and pharmacodynamics of macrolides expands, the role of these agents in treatment of these infections may be questioned. Recently issued sinusitis guidelines list blactams and cephalosporins as first-line agents, followed by fluoroquinolones, with macrolides being recommended only for b-lactam-allergic patients [8] . Macrolides were not included as first line agents despite high (defined by traditional MICs) susceptibility rates, because these guidelines accounted for "susceptibility" by use of a combination of achievable antibiotic concentrations and MICs. These pharmacokinetic and pharmacodynamic analyses demonstrate that almost all of these guidelines allow for the appropriate concentration-to-susceptibility ratios [9] . The clinical utility of this approach is still evolving, as guidelines have begun to adopt these concepts, but "discordant" treatment continues in the community without significant alarm. It appears that these strains retain clinical activity despite higher MICs.
The most recent guidelines, used widely as a source for treatment modalities, suggest that, for mild exacerbations of chronic bronchitis, either no treatment or therapy with ampicillin or doxycycline may be effective [7] . For AECB, several suggestions are provided, including therapy with macrolides and newer fluoroquinolones. However, as our understanding of antimicrobial resistance in H. influenzae and other respiratory pathogens evolves, our recommendations will evolve as well to incorporate pharmacokinetics and pharmacodynamics, resistance trends, and other scientific findings.
The strains from the LIBRA TARGETed surveillance program shown in table 1, despite being classified as macrolide susceptible by traditional MICs, may in fact be nonsusceptible because the concentrations achieved at the site of action are not sufficient to kill the strains. The TARGETed surveillance is an ongoing part of the LIBRA initiative, with details available at the LIBRA Web site [10] . The surveillance has evolved from a compilation of data from multiple studies dealing with the main respiratory tract infection (RTI) and urinary tract infection (UTI) pathogens to a single global surveillance study. As a single study, TARGETed surveillance is positioned to identify not only resistance trends in RTI and UTI pathogens, but also resistance trends in these pathogens that are based on stratification demographics (by indication, by patient characteristic, etc.). The program collects data from sites in North America, Europe, and Africa. For 2003, those data showed that 100% of H. influenzae were susceptible to levofloxacin, gatifloxacin and moxifloxacin (data on file) and to amoxicillin-clavulanate (table 1) . Data from the SENTRY surveillance database for 1997-2001 also showed fluoroquinolones to be fully susceptible, despite differences in resistance rates for b-lactams and macrolides (table 2) [11, 12] .
Although all these studies have shown that H. influenzae remains highly susceptible to fluoroquinolones caution must be observed. Recent in vitro laboratory data have shown that H. influenzae exposed to fluoroquinolones can produce mutants with several alterations in the quinolone-resistance-determining region, even though they do not appear to be resistant by standard testing methods. At MICs of 0.5 mg/L, the newer fluoroquinolone strains can have alterations in gyrA and parC [13] . Additionally, reports of clonal spread of quinolone resistance have emerged [14] . The concern is that such phe- nomena may translate into clinical failures, similar to the increased target site alterations observed with Streptococcus pneumoniae, which have been followed by reported clinical failures with levofloxacin treatment [14] .
DISCUSSION
H. influenzae has remained surprisingly susceptible to several classes of antimicrobial agents, including the b-lactam inhibitor combinations, fluoroquinolones, and (by traditional MICs) the macrolides, with the exception of clarithromycin. For the most part, these data suggest that empiric therapy with several antimicrobial agents could be used without significant concern of resistance development. However, as our understanding of pharmacokinetics and pharmacodynamics expands, we are able to further refine treatment recommendations. For example, although most macrolides except clarithromycin appear to retain near full activity against strains with the use of traditional susceptibility measures, advanced means of defining resistance breakpoints question the utility of this class against these strains. Furthermore, while in some countries (e.g., South Africa) it might also seem possible to use ampicillin because resistance rates are still low (6%), that may be wishful thinking. The lessons of other organisms, such as S. pneumoniae, suggest otherwise. The use of newer methods to guide resistance breakpoints (and dosing) is a clear start. Continued surveillance of these pathogens is essential for this process and for monitoring the efficacy of antibacterial interventions. We need to take the lessons learned from other organisms and apply them where appropriate to H. influenzae. On the basis of traditional susceptibility measures, besides the continuing presence of b-lactamase-producing strains, there appears to be no clear trend in development of resistance in this organism, as has been observed for the other major respiratory pathogen, S. pneumoniae. Both species may coexist in the respiratory tract, yet significant resistance to some agents such as the macrolides has occurred in S. pneumoniae but not in H. influenzae. In such cases, we need to look at our definitions of "resistance" carefully.
Similarly, fluoroquinolone resistance has only rarely been observed in H. influenzae-the question remains as to how best preserve this. Reports of fluoroquinolone target-site resistance in S. pneumoniae and subsequent clinical failure with levofloxacin, an agent commonly used for respiratory tract infections, raise general concerns. It is unknown whether this same phenomenon may occur with H. influenzae. There are some interesting data from patients with cystic fibrosis that suggest that long-term colonization with H. influenzae may lead to the development of hypermutable clones with higher resistance rates (14.5% vs. 1.4% in patients without cystic fibrosis) [15] . Many of these patients are treated with combination regimens of antimicrobials that include aminoglycosides (e.g., tobramycin) alternated with ciprofloxacin to try to prevent development of resistance.
Laboratory surveillance of these pathogens is important. There are several existing surveillance systems that provide an essential mechanism to follow these trends in a comprehensive, accurate, and timely manner (TARGETeD surveillance, SEN-TRY, MYSTIC, etc.) [16] [17] [18] [19] . The accuracy of the data is critical. It is important that laboratories perform testing in accordance with the same standardized methods and report the results in accordance with established criteria. Furthermore, it is important to put these findings in context, as laboratory breakpoints may not adequately capture resistance phenomena taking place at the genetic level. Surveillance conducted by testing organisms at lower concentrations may elucidate resistance mechanisms that are not captured by doubling dilution MICs. This type of surveillance will only improve the quality of information that antibiotic advisory groups, infection control programs, and public health officials can use to tailor antimicrobial use protocols in hospitals and the community.
Because the present findings suggest only significant b-lactamase activity (i.e., ampicillin resistance), many laboratories only look for this resistance determinant. Japanese surveillance data suggest that b-lactamase-nonproducing strains (BLNAR) of type b are prevalent in that country and that the prevalence has increased from 1999 (0%) to 2002 (20.3%) [20] . Of particular concern in these studies, 9.1% of these strains were also resistant to amoxicillin-clavulanate. They have specific substitutions in the genes encoding for penicillin-binding protein 3.
We have observed the rise of resistance in other organisms (e.g., MRSA), and the appearance of vancomycin-resistant S. aureus is added to the list. We do not know how or whether this will play out in H. influenzae, but observations from global surveillance programs should prompt us to be wary. In addition, not all laboratories participate in global resistance programs. If resistant strains of H. influenzae are to be discovered, laboratories will need to work closely with clinicians. Also, local laboratories need to communicate with reference laboratories that have the capability to identify resistance determinants.
H. influenzae is predominantly found in community-acquired infections; many of these, such as sinusitis and AECB, are treated empirically. Our understanding of resistance in this bacterium comes mainly from data on patients who are hospitalized and in whose sputum specimens we identify H. influenzae. We do not have a clear understanding of either resistance in the community or clonal spread of H. influenzae in that setting, although cystic fibrosis data suggest that clonal spread is likely. The experience acquired with S. pneumoniae may prove useful in preventing the spread of resistant H. influenzae.
THE FUTURE AND NEXT STEPS
The future of antimicrobial efficacy against H. influenzae is difficult to predict. Current antimicrobial use guidelines for CAP, AECB, and sinusitis are broad. Resistance potential, based on pharmacokinetic and pharmacodynamic parameters or observed trends, needs to be considered as we prescribe antibiotics for H. influenzae or other pathogens.
Infection prevention measures and control are the cornerstones in curbing resistance trends and need to be applied to H. influenzae as well as to all other organisms. Resistance trends need to be continually tracked to guide proactive and reactive measures. Ongoing surveillance of H. influenzae resistance determinants from global surveillance systems will be important to monitor and may help predict how this organism might elude current antimicrobial regimens. Strategies will be needed to define when H. influenzae needs to be treated, and newer methodologies, such as the use of pharmacokinetic and pharmacodynamic breakpoints that incorporate achievable drug levels and required exposure ratios, will help optimize therapy.
In addition to ongoing surveillance, appropriate treatment measures are essential to interrupt the apparently inevitable spiral of antimicrobial resistance. Although H. influenzae appears to be slower than other species in its broad acquisition of resistance determinants, this resistance will inevitably occur unless global steps are taken to identify and publicize these problems, establish policies for prudent antimicrobial use, and apply these policies at the local level.
